THPO and autoimmune thrombocytopenic purpura: Eltrombapag (SB-497115) as thrombopoietin stimulant agent has been approved by FDA and demonstrated that it can significantly increase the platelet counts in relapsed and refractory ITP patients (Bussel et al. 2007; Cheng et al. 2011).